SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Microvast Holdings, Inc. is an advanced battery technology company. It engages in the business of designing, developing, and manufacturing battery components and systems primarily for electric commercial vehicles and utility-scale energy storage systems. The company was founded by Yang Wu on October 12, 2006 and is headquartered in Stafford, TX.

Microvast Holdings Inc

Microvast ($MVST) is surging, with the community focused on its potential for a short squeeze and its progress in EU revenues. Many believe $MVST is undervalued compared to peers and anticipate a significant move upwards, fueled by positive technical indicators and upcoming earnings. The community is actively discussing its small float, low short interest, and potential for further growth.

United States Antimony Corp. engages in the extraction, processing and sale of antimony, zeolite, silver, and gold products. It operates through the following segments: United States Antimony Operations, Mexican Antimony Operations, Precious Metals Recovery, and United States Zeolite Operations. The company was founded by John C. Lawrence in June 1968 and is headquartered in Thompson Falls, MT.

United States Antimony Corp.

United States Antimony Corp

UAMY is trending amid discussions of potential government contracts and increasing demand for antimony, particularly with China limiting exports. Community members are debating whether to hold for long-term gains or take profits after the recent surge, with some speculating about a potential short squeeze. The stock's performance is also being compared to other companies in the rare earth and critical minerals sector.

Omeros Corp. operates as a biopharmaceutical company. The firm engages in the discovery, development, and commercializing of both small-molecule and protein therapeutics for large market. It also offers orphan indications targeting inflammation, coagulopathies, and disorders of the central nervous system. The company was founded by Gregory A. Demopulos and Pamela Pierce Palmer on June 16, 1994 and is headquartered in Seattle, WA.

Omeros Corporation

Omeros ($OMER) is trending due to a surprise $2.1 billion deal with Novo Nordisk, sparking significant investor excitement. The community is focused on the potential for milestone payments and royalties, with many speculating about a potential short squeeze and a re-rating of the stock. Traders are closely watching resistance levels, debating whether to secure profits or hold for further gains based on the news.

Root, Inc. is a technology insurance company, which engages in the provision of insurance services. It offers mobile telematics and technology platforms to segment individual risk based on complex behavioral data and customer experience to make pricing decisions and grow businesses. It provides insurance products and services in the United States. The company was founded by Alexander E. Timm and Daniel Manges in February 2015 and is headquartered in Columbus, OH.

Root Inc - Ordinary Shares - Class A

Root Inc

ROOT is trending as investors discuss potential catalysts, including partnerships and upcoming earnings, with a focus on PIF growth. Community members are debating the company's long-term potential against its current valuation, profitability, and the CEO's performance. Some traders are noting technical indicators and potential short squeezes, while others express concern over management and recent price action compared to peers.

MP Materials Corp. engages in the production and marketing of rare earth specialty materials. It operates through the Materials and Magnetics segments. The Materials segment focuses on the operation of Mountain Pass, which produces refined rare earth oxides and related products, as well as rare earth concentrate products. The Magnetics segment is involved in the operation of Independence Facility, where the company began production of magnetic precursor products. The company was founded by James Henry Litinsky and Michael Rosenthal in 2017 and is headquartered in Las Vegas, NV.

MP Materials Corporation

MP Materials is trending as discussions revolve around its potential to benefit from increased U.S. focus on rare earth independence amid escalating trade tensions with China. Community members are weighing the impact of potential government investments and supply chain shifts. Bullish sentiment is tempered by concerns about overvaluation and potential pullbacks, with some traders actively trading the volatility.

Xeris Biopharma Holdings, Inc. is a biopharmaceutical company, which engages in developing and commercializing products across a range of therapies. The company has three commercial products: Gvoke, Keveyis, and Recorlev. Gvoke is ready-to-use liquid glucagon for the treatment of severe hypoglycemia. Keveyis is the therapy approved in the United States to treat hyperkalemic, hypokalemic, and related variants of primary periodic paralysis (PPP). Recorlev is a cortisol synthesis inhibitor approved for the treatment of endogenous hypercortisolemia in adult patients with Cushing’s syndrome. Its product also includes Ogluo which is used for the treatment of severe hypoglycemia in adults, adolescents, and children aged 2 years and over with diabetes mellitus. The company was founded by Steven Prestrelski in 2005 and is headquartered in Chicago, IL.

Xeris Biopharma Holdings Inc

Xeris Biopharma is trending due to a strong earnings report and raised guidance, sparking optimism about its growth trajectory and potential profitability; the community is actively discussing the company's prospects, with some speculating about a possible buyout, fueled by increased volume and a breakout above key resistance levels.

Taiwan Semiconductor Manufacturing Co., Ltd. engages in the manufacture and sale of integrated circuits and wafer semiconductor devices. Its chips are used in personal computers and peripheral products, information applications, wired and wireless communications systems products, and automotive and industrial equipment including consumer electronics such as digital video compact disc player, digital television, game consoles, and digital cameras. The company was founded by Chung Mou Chang on February 21, 1987 and is headquartered in Hsinchu, Taiwan.

Taiwan Semiconductor Manufacturing - ADR

TSM is trending as investors anticipate upcoming earnings results amid a boom in AI-related spending and strong demand for semiconductors. Community discussions revolve around potential earnings volatility and the overall strength of the AI infrastructure market, with some highlighting TSM's critical role as a chip supplier. Recent news points to increasing data center activity and partnerships within the AI sector, potentially boosting TSM's prospects.

Sadot Group, Inc. operates as a restaurant chain business. It operates through the following segments: Muscle Maker Grill Restaurant, Pokemoto Hawaiian Poke Restaurant, Non-Traditional (Hybrid), SuperFit Foods Meal Prep, and Sadot. The firm offers protein- based meals featuring chicken, seafood, pasta, hamburgers, wraps and flat breads. It also provides salads, protein shakes and fruit smoothies. The company was founded by Rodney C. Silva in 2022 and is headquartered in Burleson, TX.

Sadot Group Inc

SDOT is trending as community members discuss its potential due to a low float and news regarding possible trade measures impacting cooking oil. Some traders are pointing to the company's potential to move into crypto, while others highlight strong revenue despite past dilution concerns. Overall, the stock sees speculative interest driven by macro events and sector momentum.

Hims & Hers Health, Inc. operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

Hims & Hers Health Inc - Ordinary Shares - Class A

Hims & Hers Health Inc

Hims & Hers Health is trending as investors discuss a potential short squeeze, with some highlighting the stock's high short interest and anticipating a breakout above the $60 resistance level. The company's recent launch of a platform for menopause and perimenopause care may be acting as a catalyst, sparking bullish sentiment, while some traders are wary of familiar resistance around the $60 mark.

Sana Biotechnology, Inc. engages in the research and development of engineered cells as medicine. It focuses on identifying and developing potential product candidates, executing preclinical studies, and acquiring technology. The company was founded by Steven D. Harr, Noubar B. Afeyan, Robert Taylor Nelsen, and Hans Edgar Bishop on July 2018 and is headquartered in Seattle, WA.

Sana Biotechnology Inc

Sana Biotechnology is trending after a hedge fund manager highlighted its potential as a "100-bagger," sparking community discussion around its technology and partnerships. The community is actively discussing the company's prospects in revolutionizing diabetes treatment and its potential for significant growth, with some questioning its valuation and potential competition. Bullish sentiment is building, driven by the breakthrough in Type 1 Diabetes treatment.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

$CYBN Really sucks lelu was right lol. If you go back to their posts in June and July when the death spiral financing was announced they literally called everything perfectly.  
 
Cybin was tracking along with all the other psychedelics until the financing. Now all the others are up making new highs, while High Trail has just been nuking the price dumping shares since then. Just gotta hope most of the $50 million has been chewed through with the elevated volume past couple of months and we start to bounce. And please god hope they don&#39;t take another $50 million tranche. 
 
Been really hard to see and super frustrating, Cybin starting to not even be mentioned along with the other psychedelic stocks any more, despite going after a larger market, with a differentiated approach, and being in phase 3 trials for MDD, and having a second asset in phase 2 for GAD.  
 
Up is down, down is up, this management team is awful.

Joe Twit

Joseph Vallancourt

Sam Porter

$CYBN completely wrong.  The convertible debenture financing announced June 30th is a strategic move to give them flexibility while looking towards commercialization, and IMO, being viewed as a potential acquisition target for another company.  

They do not want to be in a cash poor position where they could be low balled; having the convertible debenture in place is strategic business planning, NOT an example of “death spiral financing”

StockTwits for iOS

Thomas Wake

StockTwits Web

Cybin Inc

 Really sucks lelu was right lol. If you go back to their posts in June and July when the death spiral financing was announced they literally called everything perfectly.  
 
Cybin was tracking along with all the other psychedelics until the financing. Now all the others are up making new highs, while High Trail has just been nuking the price dumping shares since then. Just gotta hope most of the $50 million has been chewed through with the elevated volume past couple of months and we start to bounce. And please god hope they don't take another $50 million tranche. 
 
Been really hard to see and super frustrating, Cybin starting to not even be mentioned along with the other psychedelic stocks any more, despite going after a larger market, with a differentiated approach, and being in phase 3 trials for MDD, and having a second asset in phase 2 for GAD.  
 
Up is down, down is up, this management team is awful.

Cameron Brucker

@cambruck7 what financing are you referring to?

@cambruck7 $CYBN I’ve seen this situation time and again. The company didn’t have strong backers like the others to put up their own money to finance, So cybn had to resort to predatory converts, this doesn’t devalue the science they have. But your right the holder just converts and dumps stock on the market all day everyday, it has a psychological affect as buyers are afraid of getting smoked as soon as they buy. Fact the stock has held in here with higher volume is encouraging. If you look at the finances they have almost the same amount of cash on the books as the others, and have a fraction of the market cap due to above noted situation. Frankly any of them could still go to zero with one failed trial. But if you can weather the storm of this financing cybn could have the best risk reward profile of any at this point.

johni rotten

Kevin

Justin

Mastacash

 I’ve seen this situation time and again. The company didn’t have strong backers like the others to put up their own money to finance, So cybn had to resort to predatory converts, this doesn’t devalue the science they have. But your right the holder just converts and dumps stock on the market all day everyday, it has a psychological affect as buyers are afraid of getting smoked as soon as they buy. Fact the stock has held in here with higher volume is encouraging. If you look at the finances they have almost the same amount of cash on the books as the others, and have a fraction of the market cap due to above noted situation. Frankly any of them could still go to zero with one failed trial. But if you can weather the storm of this financing cybn could have the best risk reward profile of any at this point.

@Mastacash Agree with you there, seem to be basing instead of grinding further down. Just been so tough to ride out seeing the thesis positively play out for Atai and Mindmed, making 3 year highs while Cybin is near all time lows, despite the most compelling science and approach. Assume management thought maybe sector tailwinds would push the price above the $10.92 sticking point in the financing, clearly did not. Any potential rally gets nuked the next day. The lack of communication from management sucks. Delaying catalysts and firing the CEO with zero updates in a month and a half sucks, and feeds right into the lack of buyer mentality. Just hoping the selling pressure ends soon, gotta be close

 Agree with you there, seem to be basing instead of grinding further down. Just been so tough to ride out seeing the thesis positively play out for Atai and Mindmed, making 3 year highs while Cybin is near all time lows, despite the most compelling science and approach. Assume management thought maybe sector tailwinds would push the price above the $10.92 sticking point in the financing, clearly did not. Any potential rally gets nuked the next day. The lack of communication from management sucks. Delaying catalysts and firing the CEO with zero updates in a month and a half sucks, and feeds right into the lack of buyer mentality. Just hoping the selling pressure ends soon, gotta be close